Prostate Cancer
Research


Volume 8 Number 8
August 2020


Home > Disciplines > Publications > Prostate Cancer Research > Volume 8, Year 2020 > Number 8, August



Contents


Diagnosis, presentation


Epidemiology, risk factors, prevention


Prognosis, outcomes


Treatment



Diagnosis, presentation


Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA.
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
N Engl J Med. 2020 Mar 5. 2020;382(10):917-928. doi: 10.1056/NEJMoa1910038. Prospective study. _




Čamdžić N, Kuskunović-Vlahovljak S, Dorić M, Radović S, Lazović Salčin E, Babić M.
Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy.
Med Glas (Zenica). 2021 Feb 1. 2021;18(1). doi: 10.17392/1204-21. Retrospective study. _




Çelen S, Gültekin A, Özlülerden Y, Mete A, Sağtaş E, Ufuk F, Yüksel D, Yağcı B, Zümrütbaş AE.
Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
Urol Int. 2020 Aug 4. 2020;104(9-10):684-691. doi: 10.1159/000509974. Retrospective study. _




de Leiris N, Leenhardt J, Boussat B, Montemagno C, Seiller A, Phan Sy O, Roux J, Laramas M, Verry C, Iriart C, Fiard G, Long JA, Descotes JL, Vuillez JP, Riou L, Djaileb L.
Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
Cancer Imaging. 2020 Aug 12. 2020;20(1):58. doi: 10.1186/s40644-020-00333-y. Retrospective study. _




Di Trapani E, Musi G, Ferro M, Cordima G, Mistretta FA, Luzzago S, Bianchi R, Cozzi G, Alessi S, Catellani M, Matei DV, Jereczek-Fossa BA, Petralia G, De Cobelli O.
Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center.
Scand J Urol. 2020 Aug 10. 2020;1-5. doi: 10.1080/21681805.2020.1798503. Retrospective study. _




Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM.
Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
BMC Cancer. 2020 Aug 5;20(1):723. doi: 10.1186/s12885-020-07192-7. Retrospective study. _




Iwamoto H, Izumi K, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Kadono Y, Mizokami A.
A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age.
Asian J Androl. 2020 Jul 28. doi: 10.4103/aja.aja_39_20. Retrospective study. _




Koseoglu E, Kordan Y, Kilic M, Sal O, Seymen H, Kiremit MC, Armutlu A, Ertoy Baydar D, Altinmakas E, Vural M, Falay O, Canda AE, Balbay D, Demirkol MO, Esen T.
Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy.
Prostate Cancer Prostatic Dis. 2020 Aug 21. doi: 10.1038/s41391-020-00270-8. Retrospective study. _




Simsek DH, Sanli Y, Engin MN, Erdem S, Sanli O.
Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D'Amico risk classification.
Eur J Nucl Med Mol Imaging. 2020 Aug 13. doi: 10.1007/s00259-020-04995-5. Retrospective study. _




Sonmez G, Tombul ST, Demirtas T, Demirtas A.
Clinical factors for predicting malignancy in patients with PSA < 10 ng/mL and PI-RADS 3 lesions.
Asia Pac J Clin Oncol. 2020 Aug 10. doi: 10.1111/ajco.13347. Prospective study. _




Teyateeti A, Khan B, Teyateeti A, Chen B, Bridhikitti J, Pan T, Peng W, Macapinlac HA, Lu Y.
Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level 0.5ng/mL.
Nucl Med Commun. 2020 Sep;41(9):906-915. doi: 10.1097/MNM.0000000000001228. Retrospective study. _




Tseng JR, Yu KJ, Liu FY, Yang LY, Hong JH, Yen TC, Pang ST, Wang LJ.
Comparison between 68Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging in patients with biochemically recurrent prostate cancer following robot-assisted radical prostatectomy.
J Formos Med Assoc. 2020 Jul 29. 2020:S0929-6646(20)30341-7. doi: 10.1016/j.jfma.2020.07.029. Prospective study. _



Epidemiology, risk factors, prevention


Lan T, Park Y, Colditz GA, Liu J, Wang M, Wu K, Giovannucci E, Sutcliffe S.
Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study.
Cancer Causes Control. 2020 Aug 2. 2020;31(10):891-904. doi: 10.1007/s10552-020-01330-z. Retrospective study. _



Prognosis, outcomes


Devos G, Berghen C, Van Eecke H, Stichele AV, Van Poppel H, Goffin K, Mai C, De Wever L, Albersen M, Everaerts W, De Meerleer G, Joniau S.
Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Cancers (Basel). 2020 Aug 13. 2020;12(8):E2271. doi: 10.3390/cancers12082271. Retrospective study. _




Gandaglia G, Ploussard G, Valerio M, Marra G, Moschini M, Martini A, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Afferi L, Rakauskas A, Gontero P, Mattei A, Montorsi F, Briganti A.
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Eur Urol Oncol. 2020 Aug 23. 2020;S2588-9311(20)30123-1. doi: 10.1016/j.euo.2020.07.008. Risk tool project. _




Lian Z, Zhang H, He Z, Ma S, Wang X, Liu R.
Impact of positive surgical margin location and perineural invasion on biochemical recurrence in patients undergoing radical prostatectomy.
World J Surg Oncol. 2020 Aug 13;18(1):201. doi: 10.1186/s12957-020-01977-7. Retrospective study. _




Rho MJ, Park J, Moon HW, Lee C, Nam S, Kim D, Kim CS, Jeon SS, Kang M, Lee JY.
Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.
PLoS One. 2020 Aug 5. 2020;15(8):e0236553. doi: 10.1371/journal.pone.0236553. Artificial intelligence project. _




Sato M, Shimada S, Watanabe M, Kawasaki Y, Sato T, Morozumi K, Mitsuzuka K, Ito A.
Expression of Ganglioside Disialosyl Globopentaosyl Ceramide in Prostate Biopsy Specimens as a Predictive Marker for Recurrence after Radical Prostatectomy.
Tohoku J Exp Med. 2020 Sep;252(1):1-8. doi: 10.1620/tjem.252.1. Retrospective study. _




Wu X, Lv D, Lei M, Cai C, Zhao Z, Eftekhar M, Gu D, Liu Y.
A 10-gene signature as a predictor of biochemical recurrence after radical prostatectomy in patients with prostate cancer and a Gleason score 7.
Oncol Lett. 2020 Jul 8. 2020;20(3):2906-2918. doi: 10.3892/ol.2020.11830. Nomogram. _



Treatment


Briganti A, Gandaglia G, Montorsi F.
Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold.
JAMA Oncol. 2020 Aug 20. doi: 10.1001/jamaoncol.2020.2829. Comment. _
Refers to: Phillips R, et al., Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020 Mar 26. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. Phase II study. _




Enikeev D, Taratkin M, Amosov A, Rivas JG, Podoinitsin A, Potoldykova N, Karageziyan M, Glybochko P, Barret E.
Whole-gland ablation therapy versus active surveillance for low-risk prostate cancer: a prospective study.
Cent European J Urol. 2020 Apr 8. 2020;73(2):127-133. doi: 10.5173/ceju.2020.0009. Prospective study. _




Matta R, Hird AE, Dvorani E, Saskin R, Nason GJ, Kulkarni G, Kodama RT, Herschorn S, Nam RK.
Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer-A population-based cohort study.
Cancer Med. 2020 Aug 5. doi: 10.1002/cam4.3341. Retrospective study. _




Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2020 Mar 26. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. Phase II study. _




Tran PT, Deek MP, Phillips RM.
Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold-Reply.
JAMA Oncol. 2020 Aug 20. doi: 10.1001/jamaoncol.2020.2842. Comment in reply. _
Refers to: Briganti A, et al., Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold. JAMA Oncol. 2020 Aug 20. doi: 10.1001/jamaoncol.2020.2829. Comment. _




Zhu Y, Liu S, Feng C, Liu C, Wang Z, Yu K, Wang J, Zeng X.
The Delivery Materials with Chemotherapy Drugs for Treatment of the Positive Margin in solid tumors.
Tissue Eng Part A. 2020 Aug 6. doi: 10.1089/ten.TEA.2020.0076. In vitro/In vivo study. _



bottom



§§§§§§§§§§§§§§§§§§§§§§§